H.C. Wainwright raised the firm’s price target on Monopar Therapeutics (MNPR) to $40 from $22 and keeps a Buy rating on the shares. The firm expects ALXN-1840 to reach the market in the U.S. in late-2025 or early-2026, earlier than its previous estimate of the second half of 2025, and reach peak sales of $425M by 2033, up from a previous estimate of $272M.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics files to sell 882,761 shares of common stock for holders
- Monopar Therapeutics initiated with an Overweight at Piper Sandler
- These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year — Here’s What Analysts Expect in 2025
- Monopar Therapeutics prices 798,655 shares at $23.79 in registered offering
- Monopar Therapeutics Achieves Milestone in Cancer Treatment